Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics-Reference-Cited by-同舟云学术

Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

Published:2020-05-19 Issue:19 Volume:323 Page:1897
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kalil Andre C.¹

Affiliation:

1. Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2763802/jama_kalil_2020_vp_200062.pdf

Reference10 articles.

1. A randomized, controlled trial of ZMapp for Ebola virus infection.;Davey;N Engl J Med,2016

2. Epidemiologic features and clinical course of patients infected With SARS-CoV-2 in Singapore.;Young;JAMA

3. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention.;Wu;JAMA

4. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome.;Arabi;Am J Respir Crit Care Med,2018

5. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients.;Lee;J Clin Virol,2004

Cited by 385 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan;Patient Preference and Adherence;2024-07

2. What are the clinical and research lessons learned from immunomodulators and other therapies during the COVID-19 pandemic?;Current Opinion in Critical Care;2024-06-19

3. True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group;Clinical Infectious Diseases;2024-03-29

4. Ethical Principles of Clinical and Translational Research;Anesthesiology Clinics;2024-02

5. Health policy and regulatory authorities: challenges of technology regulation in Public Health Emergencies;Ciência & Saúde Coletiva;2024